Companies selling athletic, outdoor, denim and casual apparel brands, from Nike and Under Armour to brand groups like Levi's, VF and PVH and apparel retailers. Results hinge on consumer demand, brand heat, inventory and tariff costs.
Theme Radar
5,015 US stocks grouped by the stories in their 32,207 annual reports. Weekly: surges, risks, spreading stories.
Group surges this quarter · 11
Several stocks sharing a story beat the market together on rising volume.
Tanker companies own fleets that carry crude oil and refined products by sea and earn day rates from charters. Rates swing with global oil trade volumes, voyage distances and the number of available ships, so sanctions, re-routing and new-ship deliveries feed straight into their business.
Members (11)
Sequencing reads DNA; long-read and next-generation approaches each have strengths. Some of these companies sell instruments and reagents, others use sequencing for diagnostics such as cancer residual-disease or genetic testing, earning from instruments, consumables and test fees.
Members (6)
Electronic warfare uses the electromagnetic spectrum to jam, deceive or protect radar and communications. These companies supply signal processing, precision timing, drones and sensors to defense customers, with revenue tied to government contracts, defense budgets and procurement timing.
Diabetes can damage retinal blood vessels, causing macular edema and retinopathy — a leading cause of adult blindness. These companies develop longer-acting anti-VEGF drugs and dual-target antibodies to cut the number of eye injections; most are still in clinical trials.
Generating power on site at factories, campuses or data centers and reusing the waste heat for heating or cooling (combined heat and power), instead of relying fully on the grid. These companies make microturbines, multi-fuel generator sets and efficiency retrofits; power-hungry data centers have drawn attention to behind-the-meter supply.
Iron ore is the main raw material for steel. The group mixes miners and royalty holders with dry-bulk shipowners that carry ore, so results hinge on steel demand — especially in China — and on ore prices and freight rates.
Head and neck cancers include nasopharyngeal, oral and laryngeal tumors. These companies develop or sell therapies for them — PD-1 immunotherapy, radio-enhancing nanoparticles, antibody-drug conjugates, bifunctional antibodies — mostly still in trials, so outcomes hinge on data and regulatory approval.
Lupus is a chronic disease in which the immune system attacks the body's own tissue. These companies are taking cancer-derived approaches such as CD19 CAR-T and B-cell antibodies into lupus and other autoimmune diseases, hoping to 'reset' the immune system; most are in early-to-mid trials.
CDMOs (contract development and manufacturing organizations) develop and manufacture drugs or medical devices for other companies and are paid per project and volume. Customers outsource to avoid building plants and to move faster; demand depends on clients' pipelines and their appetite to outsource.
Members (6)
ASICs are chips designed for a single task, faster and more power-efficient than general-purpose chips. Most companies in this group make Bitcoin-mining ASICs or run mining farms, plus a lidar maker and a secure-chip maker — not quite the same as the 'custom AI chip' story.
Crash risk: the most fragile themes · 12
Scored on 8 items; listed are the riskiest 2% of themes. A risk ranking, not a short call.
Listed companies that convert treasury cash into Solana (SOL) tokens and stake them for yield; many were small companies in unrelated businesses. Shares mostly track SOL and the company's ability to keep raising money to buy more.
These companies hold Bitcoin or other tokens as their main treasury asset, usually funded by issuing stock or convertibles, so their shares amplify token-price swings. Within a year many small drug and consumer companies pivoted into 'crypto treasury' firms, often with heavy dilution.
These companies build satellites, lunar landers and spacecraft; some also launch rockets, run constellations and sell space-based data. Revenue leans on government and defense contracts, spending on development and launches is heavy, and outcomes depend on mission timelines and orders.
eVTOLs are electric aircraft that take off and land vertically, meant to carry passengers on short city hops like an air taxi. Most of these companies are still in development and certification with little or no revenue, funded by capital raises; certification and production timing are what matter.
Quantum computers compute with qubits and could beat classical machines on certain problems, though large-scale use is still far off. The group mixes dedicated hardware and software firms with giants like IBM and government tech contractors; the pure plays have small revenue and rely on fundraising.
Inference is when a trained AI model actually answers queries or generates content, and it grows as AI apps spread. The group includes GPU cloud providers, bitcoin miners converting sites into compute centers, and makers or licensors of edge inference chips.
Companies making military and commercial drones and unmanned vehicles, plus their batteries, composites and sensors. Defense budgets and battlefield lessons are lifting demand, but many members are small and loss-making, with orders concentrated in government and military customers.
Biotechs whose annual reports center on drugs in Phase 1–3 trials. Most have no approved product or steady revenue and fund research by selling stock and licensing deals, so shares move on trial data, regulatory decisions and financing.
Natural killer cells are immune cells that directly kill cancer and virus-infected cells. These companies turn NK or iPSC-derived immune cells into off-the-shelf therapies for cancer and autoimmune disease; most are in early-to-mid trials.
New drugs for cancers that have already spread, such as metastatic colorectal cancer and melanoma, including PD-1 combinations, cell therapies and conditionally activated antibodies. Urgent patient need; shares swing hard on trial readouts.
Counter-drone systems detect drones with radar, electro-optical and infrared sensors, then jam, intercept or disable them, including with directed energy. These companies make the sensors, autonomous defense systems and defense electronics, with demand from militaries and critical-site protection.
These drug developers in-license their lead candidates from other companies, recently often Chinese biotechs, buying ex-China rights and then running trials and launches themselves. It is a faster start, paid for with upfront and milestone fees, and success still depends on trial data.
Contract waves: themes whose members are signing more · 12
Members are signing more contracts than usual; tap "latest" for the filing. Not a bullish signal.
Training and running AI models takes huge amounts of chips, memory, servers, cooling and power. This group spans chips, memory, server manufacturing, chip equipment and AI PCs — the 'picks and shovels' story: more AI use means more hardware demand.
Companies renting AI compute and cloud platforms, from large clouds and edge networks to bitcoin miners converting sites into GPU data centers, plus suppliers of servers and battery storage to them. The business depends on securing GPUs and power; customers train and run large models.
Drugmakers treating rare genetic, metabolic, neurological and blood disorders. Few patients but high prices, often with orphan-drug incentives and exclusivity; trial data, approvals and launch uptake drive the story.
Operators, equipment makers and chip suppliers building broadband, 5G cell sites and fiber networks. Spending follows carriers and government broadband subsidies; equipment orders are lumpy.
The largest US shale oil and gas basin (West Texas and New Mexico): producers, land and royalty owners, and service firms handling compression and produced water. Oil prices, output and pipeline takeaway capacity are key.
Grocers, shopping-center REITs anchored by supermarkets, and food brands selling through them. Staples with steady traffic; grocery-anchored centers have low vacancy and stable rents.
Drugmakers copying biologic medicines (antibodies, insulin, etc.) after patents expire. Harder to develop and make than generic pills; the patent-cliff calendar, approvals and substitution rules decide the market.
Lenders, platforms and mortgage REITs making loans against home equity (HELOCs, second liens). With high rates, owners keep their cheap first mortgages and tap equity instead, boosting demand; credit and home prices are the risks.
Companies buying and collecting non-performing loans and charged-off debt, plus REITs investing in non-QM residential mortgages. Downturns raise supply and lower purchase prices, but recoveries and funding costs decide profits.
Companies using platforms to find drugs at scale: antibody discovery, AI-driven drug design and DNA synthesis. Revenue often comes from partnership upfronts and milestones with big pharma; in-house pipelines are early.
This counts companies that talk about AI in their annual reports, not just AI vendors: chipmakers, software, insurers, distributors and industrials all now describe AI in their business. The surge shows AI has become a near-universal talking point, so on its own it does not tell who actually earns from it.
Platforms and ad-tech firms selling ads on connected TVs and streaming: TV operating systems, programmatic exchanges and ad verification. The long-run driver is ad budgets shifting from linear TV to streaming.
Supply pressure: themes whose members are issuing shares · 12
Members are issuing lots of new shares. Historically this tier trailed the market by 9.5% (median) over a year.
Listed companies that convert treasury cash into Solana (SOL) tokens and stake them for yield; many were small companies in unrelated businesses. Shares mostly track SOL and the company's ability to keep raising money to buy more.
Staking locks tokens into a blockchain network to help validate transactions in exchange for yield-like rewards. Within a year many 'token treasury' companies appeared, buying and staking Ether, Solana, SUI, TAO and other tokens — often unrelated to their original business.
Digital assets are on-chain holdings such as Bitcoin, Ether and stablecoins. The number of companies telling this story jumped within a year: exchanges, custodians and tokenization providers, miners, and many small companies putting crypto on their balance sheets.
Companies building blockchain networks, protocols, validator nodes and on-chain payments, including older businesses pivoting to blockchain. Revenue comes from fees, staking rewards and tech services, and moves closely with crypto prices.
These companies hold Bitcoin or other tokens as their main treasury asset, usually funded by issuing stock or convertibles, so their shares amplify token-price swings. Within a year many small drug and consumer companies pivoted into 'crypto treasury' firms, often with heavy dilution.
Drug developers that buy regional rights to medicines discovered elsewhere (recently often in China) and run the trials and launch themselves. What matters is the licensed drug's clinical data and the upfront and milestone payments.
Drugs that harness the patient's immune system to attack cancer or rebalance immunity, including peptide vaccines and T-cell engagers. Mostly clinical-stage companies whose shares hinge on trial results.
GPUs are the core chips for training and running AI models. Besides the chipmaker, the group includes many 'GPU cloud' firms that build data centers, buy GPUs and rent compute by the hour — many converted from Bitcoin mining and all capital-intensive.
Companies testing blood, stool, tissue or DNA to screen for and diagnose cancer. Revenue depends on test volume and reimbursement; clinical evidence and getting into coverage and guidelines are key.
Re-engineering drugs as prodrugs that activate inside the body, or as new oral or long-acting forms, to improve absorption, side effects and convenience. Lower risk than brand-new drugs, but patents and exclusivity decide the value.
New drugs for cancers that have already spread, such as metastatic colorectal cancer and melanoma, including PD-1 combinations, cell therapies and conditionally activated antibodies. Urgent patient need; shares swing hard on trial readouts.
New drugs for Crohn's disease and ulcerative colitis, including oral small molecules and antibodies. Existing treatments help only part of patients and the market is large; efficacy and oral dosing are what investors watch.
M&A waves: themes whose members are in deals · 6
3+ members are in merger deals. Historically fewer crashes and fewer big gains. Not a bullish signal.
The Internet of Things connects devices so they can talk to each other and be managed remotely, from smart homes and industrial sensors to meters and connected cars. The group mixes chipmakers selling connectivity chips and microcontrollers with IoT platforms, module makers and carriers.
Companies that design and make chips, plus suppliers of equipment, materials, test instruments and design software. A broad industry group spanning analog, power, RF, memory and discrete devices, cycling with demand from autos, industry, communications and data centers.
Chips, sensors, cockpit displays and battery-management systems make up a growing share of every car as electrification and driver assistance spread. The group includes automotive chip and component makers, lidar and vision firms and cockpit-electronics suppliers, tied to vehicle output and the pace of electrification.
Makers of electric cars, pickups and commercial vehicles, plus battery, drivetrain and parts suppliers. The industry runs on subsidies, battery costs and charging networks; most newer automakers still lose money and raise capital, and price wars and tariffs weigh heavily.
Electric, gas and water utilities whose rates and allowed returns are set by regulators, giving steady revenue and high dividends. The current story is grid investment driven by data-center power demand, plus consolidation within the industry.
Suppliers of seals, fuel systems, cockpit electronics, thermal management, sensors and other parts to automakers. Business follows vehicle production, model changeovers and electrification, margins are thin, and raw-material and tariff costs matter.
Spreading stories
Stories with the biggest one-year rise in companies telling them in annual reports.
This counts companies that talk about AI in their annual reports, not just AI vendors: chipmakers, software, insurers, distributors and industrials all now describe AI in their business. The surge shows AI has become a near-universal talking point, so on its own it does not tell who actually earns from it.
Digital assets are on-chain holdings such as Bitcoin, Ether and stablecoins. The number of companies telling this story jumped within a year: exchanges, custodians and tokenization providers, miners, and many small companies putting crypto on their balance sheets.
AI agents are programs that break down tasks, call tools and complete multi-step work on their own — a step beyond chatbots. Many software firms in customer service, HR, CRM and marketing data now say their products include agents, charged by subscription or usage.
Training and running AI models takes huge amounts of chips, memory, servers, cooling and power. This group spans chips, memory, server manufacturing, chip equipment and AI PCs — the 'picks and shovels' story: more AI use means more hardware demand.
AI infrastructure means the data centers, networks, power and construction that host AI. Some companies here build facilities and lay cable, others make networking gear, storage and electronics, and some former Bitcoin miners are converting to host AI compute.
Staking locks tokens into a blockchain network to help validate transactions in exchange for yield-like rewards. Within a year many 'token treasury' companies appeared, buying and staking Ether, Solana, SUI, TAO and other tokens — often unrelated to their original business.
These companies hold Bitcoin or other tokens as their main treasury asset, usually funded by issuing stock or convertibles, so their shares amplify token-price swings. Within a year many small drug and consumer companies pivoted into 'crypto treasury' firms, often with heavy dilution.
Critical minerals such as antimony, lithium, rare earths, nickel and cobalt are vital for defense, batteries and electronics, with supply concentrated in a few countries. As the US pushes domestic supply chains, more explorers, processors, recyclers — even coal miners — tell this story; most are pre-revenue developers.
GPUs are the core chips for training and running AI models. Besides the chipmaker, the group includes many 'GPU cloud' firms that build data centers, buy GPUs and rent compute by the hour — many converted from Bitcoin mining and all capital-intensive.
Digital health moves care online: virtual visits, online pharmacies, physician platforms and connected devices. These companies earn from subscriptions, visit fees or insurer payments, so reimbursement rules and customer-acquisition costs matter most.
IoT connects cars, factory equipment and appliances to networks. This group is mostly makers of wireless chips, modules and network equipment, plus telecom carriers, with revenue tied to shipments of phones, cars and industrial gear.
Private credit is lending to mid-sized companies by non-bank funds, usually at higher rates. The group is mostly BDCs (business development companies) and alternative asset managers earning loan interest and management fees; the key risk is defaults in a downturn.
Liquefied natural gas (LNG) is gas cooled into liquid so it can be shipped overseas. These companies build and operate export terminals, pipelines and storage, or provide the engineering, with revenue mostly from long-term contracts and projects.
Rising aircraft deliveries pull through suppliers of engine parts, fasteners, specialty alloys and avionics. These companies supply commercial and military aircraft; programs are long, certification barriers high, and capacity and materials are the bottlenecks.
These companies supply militaries with drones, missile defense, military communications, displays and specialty materials, mostly under government contracts. With geopolitical conflict and rising defense budgets, noticeably more companies are telling a defense story.
Fiber optics carries data as light and is the backbone of broadband and data-center links. The group includes fiber and optical-component makers, network-equipment vendors, cable-laying contractors and carriers; high-speed links between AI data centers are the new source of demand.
Autonomy lets cars, trucks, drones and robots perceive their surroundings and move on their own. The group covers lidar and sensor makers, drone companies, automakers and compute-chip suppliers; most are still investing heavily, and commercialization timing is the core question.
Not investment advice. Latest filing 2026-10-16, generated 2026-10-20.